What is it about?
This paper reports on the opportunistic yeast (Candida) species associated with HIV infection in 2 groups from South Africa and Cameroon and describes their response (or lack of it) to the anti-fungal drugs routinely administered for treatment or prophylaxis.
Featured Image
Why is it important?
Many HIV-associated Candida species have developed a resistance to the azole drugs. Regular reports of species prevalence and antimicrobial profiles are essential to control opportunistic infections in HIV patients.
Perspectives
Africa has the highest rate of HIV infection and opportunistic infections need to be controlled to reduce mortality rates. Regular surveillance of opportunistic pathogens and their susceptibility to drugs routinely available at HIV clinics informs adequate treatment . Failure to do so will result in the spread of resistant species which is highly problematic.
Emerita Professor Charlene WJ Africa
University of the Western Cape
Read the Original
This page is a summary of: Multi-drug resistant oral Candida species isolated from HIV-positive patients in South Africa and Cameroon, Diagnostic Microbiology and Infectious Disease, June 2014, Elsevier, DOI: 10.1016/j.diagmicrobio.2013.09.016.
You can read the full text:
Contributors
The following have contributed to this page
